[go: up one dir, main page]

CN102532084B - One class coumarin kind compound, Preparation Method And The Use - Google Patents

One class coumarin kind compound, Preparation Method And The Use Download PDF

Info

Publication number
CN102532084B
CN102532084B CN201010611115.6A CN201010611115A CN102532084B CN 102532084 B CN102532084 B CN 102532084B CN 201010611115 A CN201010611115 A CN 201010611115A CN 102532084 B CN102532084 B CN 102532084B
Authority
CN
China
Prior art keywords
compound
preparation
compd
cancer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201010611115.6A
Other languages
Chinese (zh)
Other versions
CN102532084A (en
Inventor
任风芝
陈书红
李丽红
郑智慧
成晓迅
张雪霞
张艳丽
高月麒
王宁
张艳哲
于兰
宋霏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NCPC New Drug Research and Development Co Ltd
Original Assignee
NCPC New Drug Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NCPC New Drug Research and Development Co Ltd filed Critical NCPC New Drug Research and Development Co Ltd
Priority to CN201010611115.6A priority Critical patent/CN102532084B/en
Publication of CN102532084A publication Critical patent/CN102532084A/en
Application granted granted Critical
Publication of CN102532084B publication Critical patent/CN102532084B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to compound, Preparation Method And The Use that a class obtains from Chinese medicine is pointed at both ends, described compound is coumarin kind compound and pharmacy acceptable salt thereof; Relate to preparation method and the pharmaceutical composition thereof of this compounds, and described compound is for the preparation of the purposes of cancer therapy drug, especially for the treatment of the cancers such as leukemia, lung cancer, colorectal carcinoma, liver cancer, sarcoma.

Description

One class coumarin kind compound, Preparation Method And The Use
Technical field
The present invention relates to compound, Preparation Method And The Use that a class obtains from Chinese medicine is pointed at both ends, described compound is coumarin kind compound and pharmacy acceptable salt thereof; Relate to preparation method and the pharmaceutical composition thereof of this compounds, and described compound is for the preparation of the purposes of cancer therapy drug, especially for the treatment of the cancers such as leukemia, lung cancer, colorectal carcinoma, liver cancer, sarcoma.
Background technology
Chinese medicine is pointed at both ends is the rhizome of ranunculaceae plant anemone raddeana Regel (Anemone raddeana Regel.), begin to be loaded in Ming Dynasty Liu Wen safe show " Bencao Pinhui Jingyao ".There is the effect of wind-damp dispelling, subduing inflammation clinically, be used for the treatment of rheumatism and arthritis, spasm of the limbs, the diseases such as carbuncle turgescence canker.Compound involved in the present invention is coumarin kind compound.
Tonka bean camphor is the general name of a class natural compounds with benzene a pair of horses going side by side α-pyrone parent nucleus, structurally can regard the lactone along coumarinic acid dehydration as.This compounds is the derivative of shikimic acid biosynthetic pathway meta-bolites; extensively be distributed in vegitabilia; particularly in higher plant; as umbelliferae (Umbelliferae), Rutaceae (Rutaceae) etc.; there is many-sided biologic activity; as antibacterial, anticancer, anticoagulation, stop blooding, relieving asthma, eliminate the phlegm, protect blood vessel, treatment stenocardia and anti-oxidant [YangXW; HattoriM; Namba T.J.Chin.Pharm.Sci.; 1996,5 (3): 132-140] etc.McCulloch etc. [McCulloch P, GeorgeWD.Br.J.Cancer, 1989,59:179-183.] report that coumarin kind compound warfarin (warfarin) can suppress the Lung metastases of the Mtln3 cancer cells of female F344 mouse; Fuskova etc. [Fuskova A, Proksa B, Fuska J.Pharmazie, 1977,32:291-293] report that coumarin kind compound reaches the effect of killing tumour cell by the synthesis of arrestin matter and nucleic acid.
Summary of the invention
The present invention through botanical anticancer screening active ingredients widely, the antitumour activity of the class coumarins composition contained during Late Cambrian Chinese medicine is pointed at both ends.
First aspect, the present invention relates to a class as shown in the formula the compound of (I) or its pharmacy acceptable salt
Wherein, R=-CH 3or-CHO.
Second aspect, the present invention relates to the preparation method of above-claimed cpd or its pharmacy acceptable salt, comprises the following steps:
1) pointed at both ends or after pulverizing the ethanol that adds pointed at both ends is extracted, obtain extracting solution;
2) by extracting liquid filtering, be concentrated into without alcohol, obtain concentrated solution;
3) concentrated solution is used sherwood oil, extraction into ethyl acetate successively, obtain extraction liquid;
4), after extraction liquid is concentrated, through column chromatography, high-pressure liquid phase is prepared and be get final product.
Wherein the volume percent range of alcohol concn is 40%-95%, and column chromatography used medium can be silica gel, aluminum oxide.
3rd aspect, the present invention relates to a kind of pharmaceutical composition, the compound containing arbitrary formula (I) or its pharmacy acceptable salt, and one or more pharmaceutically acceptable carrier or vehicle.Physico-chemical property and the spectral data of described formula (I) compound are as follows:
Compd A (R=-CH 3): faint yellow needle, molecular formula C 12h 12o 5, ESI-MS molecular weight 236, according to 1hNMR, 13cNMR, 1h- 1h COSY, DEPT, HSQC, HMBC, ESI-MS etc., confirm that this compound is: 4,7-dimethoxy-5-methyl-6-Hydroxycoumarins.
The spectral data (DMSO) of table 1 compd A
Compd B (R=-CHO): white needles, molecular formula C 12h 10o 6, ESI-MS molecular weight 250, comprehensively analyzes 1hNMR, 13cNMR, 1h- 1h COSY, HSQC, HMBC etc., confirm that this compound is: 4,7-dimethoxy-5-aldehyde radical-6-Hydroxycoumarins.
Spectral data (the CDCl of table 2 compd B 3)
4th aspect, the present invention relates to pharmaceutical composition described in described compound or its pharmacy acceptable salt and the third aspect and is preparing the purposes in cancer therapy drug.Cancer is wherein leukemia, lung cancer, colorectal carcinoma, liver cancer, sarcoma.
Human leukocyte elastase (human leukocyte elastase HLE) is a kind of main proteolytic enzyme in human body, and its direct effect substrate is the extracellular matrix such as elastin, collagen protein, protein-polysaccharide in the reticular tissue such as lung, liver, kidney.In body, the too much or hyperactivity of elastoser expression of enzymes all can cause serious tissue injury, and causes or increase the weight of the diseases such as multiple pulmonary emphysema, chronic bronchitis, pyemia, ephritis, rheumatoid arthritis and some skin disease.In addition because elastoser can destroy collegen filament and Tissue Base rete, play a crucial role in the formation and metastases of tumour, so elastoser becomes action target spot [the Dona M of PTS, Dell Aica I, Pezzato E, et al.Hyperforin inhibits cancer invasion and metastasis.Cancer Res, 2004, 64 (17): 6225.Sun Z, Yang P.Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression.Lancet Oncol, 2004, 5 (3): 182].
Confirm through experiment, compd A of the present invention and B have obvious restraining effect to HLE, and present good concentration dependant sexual intercourse.
Retinoid receptor (RAR) is present in nucleus, it can mediate the effect of vitamin A acid (vitamin A oxidation metabolites in vivo), regulate the expression of target gene, thus play a significant role in the growth, atomization of the maintenance of animal life and body.RAR albumen is made up of six functional domains such as A, B, C, D, E, F.Wherein A, B are genetic transcription regulatory region; C district is DNA land; E is vitamin A acid land, forms dimer after E district binding partner, and then C district is combined with DNA and then regulatory gene is expressed.Now determine the RAR of three types: i.e. RAR α, RAR β and RAR γ.The generation of acute promyelocytic leukemia (APL) is due to t (15 mostly; 17) chromosome translocation, and t (15; 17) chromosome translocation be by Retinoic Acid Receptor Alpha 1 gene (RARA) on the PML gene on No. 15 karyomit(e)s and No. 17 karyomit(e)s between rearrangement caused by.So become the key for the treatment of acute promyelocytic leukemia for the research of Retinoic Acid Receptor Alpha, this model is the high flux screening model based on Mammalian one-hybrid system built for retinoid receptor, for screening lead compound [the AlBahar S for the treatment of acute promyelocytic leukemia, Pandita R, Bavishi K, et al.All trans-retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.Indian J Cancer, 2004, 41 (3): 125-128].
Confirm through experiment, compd A of the present invention and B have obvious agonist activity to retinoid receptor.
In addition, confirm through experimentation on animals, the compd A that the present invention relates to, B have obvious therapeutic action to cancer mouse.
And compd A of the present invention, B do not have cytotoxicity to normal cell.
Formula (I) compound that the present invention relates to or its pharmacy acceptable salt, all can use separately or with other anti-cancer agent in combination.
Pharmaceutical composition of the present invention contains arbitrary formula (I) compound or its pharmacy acceptable salt, and one or more pharmaceutically acceptable carriers or vehicle, described carrier or vehicle comprise carrier and the vehicle of the application of pharmaceutics routine, as weighting agent, tamanori, sanitas, correctives, thinner, tinting material etc.According to the ordinary method of art of pharmacy, formula of the present invention (I) compound or its pharmacy acceptable salt, all can make the formulation of the administering modes such as applicable oral, injection, as: tablet, capsule, injection etc.
According to the understanding of those of ordinary skill in the art, the dosage of compd A, B should be determined according to factors such as the age for the treatment of target, body weight and disease severities, can be generally 30mg/d.
Accompanying drawing explanation
Accompanying drawing 1: compd A 1h-NMR collection of illustrative plates
Accompanying drawing 2: compd A 13c-NMR collection of illustrative plates
Accompanying drawing 3: the DEPT spectrum of compd A
Accompanying drawing 4: the ESI-MS collection of illustrative plates of compd A
Accompanying drawing 5: compd A 1h- 1h COSY collection of illustrative plates
Accompanying drawing 6: the HSQC collection of illustrative plates of compd A
Accompanying drawing 7: the HMBC collection of illustrative plates of compd A
Accompanying drawing 8: compd B 1h-NMR collection of illustrative plates
Accompanying drawing 9: compd B 13c-NMR collection of illustrative plates
Accompanying drawing 10: the ESI-MS collection of illustrative plates of compd B
Accompanying drawing 11: compd B 1h- 1h COSY collection of illustrative plates
Accompanying drawing 12: the HSQC collection of illustrative plates of compd B
Accompanying drawing 13: the HMBC collection of illustrative plates of compd B
Embodiment
The following examples, experimental example will do more detailed description to the present invention, and they are not construed as limiting the invention.Except non-specifically is explained, in the present invention, all per-cent is volume percent.
Chinese medicine (Chinese Pharmacopoeia) pointed at both ends: Shijiazhuang Le Rentang company limited
Column chromatography silica gel (300-400 order): Haiyang Chemical Plant, Qingdao
Thin-layer chromatography silica-gel plate and trifluoroacetic acid aqueous solution: Merck & Co., Inc.
HPLC：Waters 996
HPLC chromatographic column: Phenomenex 250 × 21.2mm, 10um
INVOA 500 type nuclear magnetic resonance spectrometer (Volian company), TMS is interior mark
ZMD Micromass type mass spectrograph: Micromass company of Britain
CO 2constant temperature cell culture incubator: SHELLAN company of the U.S.
PMI1640 nutrient solution: GIBCO company
MTT:Sigma company
Leukemia K562 cell: American Type Culture Collecti
Human lung cancer cell A549: American Type Culture Collecti
Human colon cancer cell HCT-15: American Type Culture Collecti
Fetal hepatocyte strain L02: Shanghai Inst. of Cytobiology, Chinese Academy of Sciences
Human leukocyte elastase (Human Leukocyte Elastase HLE): Sigma company
Peptide substrate (N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide): Sigma company
Lipofectamine 2000Reagent:invitrogen company
Victor more than 21420 marks calculating instrument: PE company of the U.S.
Embodiment: the preparation of formula (I) compound
By 2.5 kilograms pointed at both ends for Chinese medicine, after pulverizing, extract with 4 times of 80% alcohol heating reflux, extract 2 times, each 2 hours, united extraction liquid, is evaporated to without alcohol, uses equal-volume sherwood oil, ethyl acetate, n-butanol extraction 2 times successively, concentrated acetic acid ethyl acetate extract is through silica gel column chromatography, petroleum ether-ethyl acetate (1: 1 volume ratio) wash-out, collects 3-4 times of column volume elutriant, concentrates to obtain 10 grams of medicinal extract; Again through silica gel column chromatography, sherwood oil-acetone gradient elution (3: 1,2: 1,1: 1), collects 2: 1 elution fraction and concentrates, obtain compd A (R through HPLC preparation (25% acetonitrile-water) t=12.6min, 73mg), compd B (R t=11.5min, 21mg).
Experimental example
The outer inhibiting tumor assay of experimental example 1:MTT body of laws
Experiment material: K562, A549, HCT-15.
Adopt conventional mtt assay.Collect and be in above-mentioned each tumour cell of logarithmic phase, with the trypsin digestion and cell of 0.25%, then with 10% RPMI1640 nutrient solution to adjust cell concn be 1.0 × 10 5/ ml, is inoculated in 96 porocyte culture plates, and every hole 100ul adds the compd A-D of different concns respectively, and negative control medicine is phosphate buffered saline buffer.Often organize and all establish 3 multiple holes.Be placed in 37 DEG C, 5%CO 272h is cultivated in incubator, terminate front 4h in cultivation, each culture hole adds 10ul MTT (5mg/ml), cultivates after terminating, suck culture supernatant, every hole adds the SDS 100ul of 10%, and concussion 10min, makes crystallisate fully dissolve, placement is spent the night, finally measure each hole OD value by microplate reader in 490nm wavelength place, carry out analysis of cell proliferation, statistic data also carries out t inspection.
Experimental result shows, and shown in extract of the present invention and formula (I), compd A, B have obvious restraining effect to K562, A549, HCT-15 Growth of Cells.They are to the IC of tumour cell 50value sees the following form:
Extract of the present invention and compd A, B are to the IC of tumour cell 50value (IC 50: ug/ml)
Experimental example 2: compd A and B are to the inhibit activities of HLE
In the sample well of 96 orifice plates, add the DMSO solution of test sample, add HLE enzyme liquid and damping fluid totally 100 μ l; Control wells DMSO replaces sample solution; Blank well replaces sample solution with DMSO and replaces enzyme liquid with damping fluid.Use 1420Victor 2many marks calculating instrument, under 410nm wavelength, reads every hole OD value (at the bottom of sample copy A1); Add substrate 100 μ l, 37 DEG C of insulation reaction read the OD value (A2) in every hole again after 120 minutes, and the inhibiting rate of calculation sample.
The compd A and the B that get concentration gradient carry out determination of activity to HLE.Two compd As and the restraining effect of B to HLE present the relation of good concentration dependent, its IC 50be respectively 27.6 μ g/mL and 59.6 μ g/mL.
Experimental example 3: compd A and B are to the agonist activity of retinoid receptor
By cell strain CHO-K1 with 3 × 10 5individual/mL cell count is inoculated in 96 orifice plates, after 24h, nutrient solution is changed into containing 10% foetal calf serum without dual anti-PRMI 1640 substratum, with Lipofectamine TM 2000Reagent, recombinant plasmid pBIND-RAR α and the pGL3-GAL4 plasmid co-transfection containing 5 GAL4 respective element and luciferase reporter gene are entered cell.The positive drug induction adding different concns after 6h stimulates, and DMSO is as blank.Cell pyrolysis liquid (EDTA is added after administration 24h, TritonX-100, Tris), after lysing cell 5min, add reaction solution (EDTA, TritonX-100, Tris, ATP, ConA, Luciferase etc.) and detect luciferase expression activity with 1420Multilabel Counter rapidly.The induced expression multiplication number of luciferase is the activity of dosing group luciferase and the ratio of blank (DMSO).The induction multiplication activity being greater than 2 times in the screening of routine is defined as positive compound.
Under different concns, compd A and B are to the multiplication number of retinoid receptor
Experimental example 4 liver cancer mouse tumor inhibition
Experiment material: BALb/c mouse inbred lines, male 8-12 age in week, body weight 20-22g, purchased from Hebei Medical University's Experimental Animal Center.H-22 liver cancer mouse, purchased from Hebei Medical University's Experimental Animal Center.
Experimental technique: aseptic aspiration lotus H-22 liver cancer mouse the 7th day ascites, with normal saline dilution 10 times, in test mice right fore armpit subcutaneous injection 0.2ml.Be divided into 5 groups at random, every treated animal 10, records simultaneously and often organizes Mouse Weight.If physiological saline group and cis-platinum positive controls, compd A, B dosage are 5.0mg/Kg, after inoculation next day continuous intraperitoneal injection 8 days, within 9th day, de-cervical vertebra puts to death animal, and record Mouse Weight, dissects and take out knurl block, weigh, calculate tumour inhibiting rate according to following formula.
Experimental result: shown in extract of the present invention and formula (I), compd A, the tumor growth of B to H-22 liver cancer mouse have certain restraining effect, and have no significant effect the body weight of mouse.
The compounds of this invention is to the tumour inhibiting rate of H-22 liver cancer mouse (BALb/c mouse)
Body weight (g) tumour inhibiting rate (%) after body weight (g) medication before group dosage (mg/kg) medication
Physiological saline--18.6 ± 1.1 20.7 ± 1.2--
Cis-platinum 2.0 19.7 ± 1.4 16.7 ± 1.8 78.8 *
Compd A 5.0 18.9 ± 1.3 19.7 ± 1.1 48.9 *
Compd B 5.0 20.1 ± 0.9 21.2 ± 0.9 40.8 *
*: P < 0.01 compared with blank group; *: P < 0.05 compared with blank group
Experimental example 5:S180 sarcoma mouse tumor inhibition
Experiment material: mouse S180, Hebei Medical University.Cleaning grade Kunming mouse, male, body weight 18-22g, purchased from Hebei province's Experimental Animal Center.Cis-platinum, Dezhou, Shandong Province pharmaceutical factory produces.
Experimental technique: adopt Kunming mouse subcutaneous vaccination S-180 sarcoma model.Knurl kind vitro culture is to logarithmic phase, and numeration, regulates cell count to be 6 × 10 6individual/ml, is inoculated in mouse right fore oxter, every 0.2ml, is divided into 5 groups at random, and every treated animal 10, records simultaneously and often organize Mouse Weight.If physiological saline group and cis-platinum blank group and attached property control group, shown in formula (I), compd A, B establish 5.0mg/Kg dosage group, after inoculation next day continuous intraperitoneal injection 8 days, within 9th day, de-cervical vertebra puts to death animal, record Mouse Weight, dissect and take out knurl block, weigh, calculate tumour inhibiting rate according to following formula.
Experimental result: formula of the present invention (I) compd A, the growth of B to S180 murine sarcoma have obvious restraining effect, and have no significant effect Mouse Weight.
Compd A, B are to the tumour inhibiting rate of Kunming kind S180 sarcoma mouse
Body weight (g) tumour inhibiting rate (%) after body weight (g) medication before group dosage (mg/kg) medication
Physiological saline--18.8 ± 1.1 20.1 ± 0.8---
Cis-platinum 2.0 19.5 ± 1.2 16.4 ± 0.7 55.8 *
Compd A 5.0 20.6 ± 0.9 21.5 ± 1.2 33.8 *
Compd B 5.0 20.4 ± 1.4 21.2 ± 1.1 29.7 *
*: P < 0.01 compared with blank group; *: P < 0.05 compared with blank group
Experimental example 6:LDH method cytotoxic assay
LDH method cytotoxicity Cleaning Principle: LDH (serum lactic dehydrogenase) is a kind of stable protein, is present in Normocellular kytoplasm, once damaged membrane, namely LDH is released to extracellular; By detecting the enzymic activity of LDH in cells and supernatant, detect cytotoxicity.
Concrete mensuration process: cell L02 is adjusted to 5 × 10 with the RPMI-1640 nutrient solution containing 5% calf serum 4~ 2 × 10 5/ ml; In 96 hole circle floor cells culture plates, add L02 cell, every hole adds 100 μ l, puts 37 DEG C of 5%CO 2cO2gas incubator in cultivate 4 ~ 6 hours; Then add test compound, be incubated 24 hours, the multiple hole of each Setup Experiments three; Get supernatant, use LDH kit measurement, enzyme connection detector measures the optical density(OD) (OD value) in each hole, determined wavelength 492nm, reference wavelength 650nm.
Measurement result shows: compd A, B do not have cytotoxicity to normal cell L02 under 0.04-100ug/ml concentration.

Claims (7)

1. a class is as shown in the formula the compound of (I) or its pharmacy acceptable salt
Wherein, R=-CH 3or-CHO.
2. a preparation method for claim 1 compound, comprises the following steps:
1) pointed at both ends or after pulverizing the ethanol that adds pointed at both ends is extracted, obtain extracting solution;
2) by extracting liquid filtering, be concentrated into without alcohol, obtain concentrated solution;
3) concentrated solution is used sherwood oil, extraction into ethyl acetate successively, obtain extraction liquid;
4), after extraction liquid is concentrated, through column chromatography, high-pressure liquid phase is prepared and be get final product.
3. preparation method according to claim 2, wherein the volume percent range of alcohol concn is 40%-95%.
4. preparation method according to claim 2, wherein column chromatography used medium is silica gel, aluminum oxide.
5. a pharmaceutical composition, containing arbitrary compound according to claim 1 or its pharmacy acceptable salt, and one or more pharmaceutically acceptable carrier or vehicle.
6. pharmaceutical composition described in compound described in claim 1 or its pharmacy acceptable salt and claim 5 is preparing the purposes in cancer therapy drug.
7. purposes according to claim 6, cancer is wherein leukemia, lung cancer, colorectal carcinoma, liver cancer, sarcoma.
CN201010611115.6A 2010-12-29 2010-12-29 One class coumarin kind compound, Preparation Method And The Use Active CN102532084B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201010611115.6A CN102532084B (en) 2010-12-29 2010-12-29 One class coumarin kind compound, Preparation Method And The Use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201010611115.6A CN102532084B (en) 2010-12-29 2010-12-29 One class coumarin kind compound, Preparation Method And The Use

Publications (2)

Publication Number Publication Date
CN102532084A CN102532084A (en) 2012-07-04
CN102532084B true CN102532084B (en) 2015-08-19

Family

ID=46340258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201010611115.6A Active CN102532084B (en) 2010-12-29 2010-12-29 One class coumarin kind compound, Preparation Method And The Use

Country Status (1)

Country Link
CN (1) CN102532084B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103408530B (en) * 2013-08-26 2015-05-27 中国人民解放军第三军医大学 Coumarin skeleton polycyclic compound with biological activity as well as preparation method and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207392A (en) * 1997-07-31 1999-02-10 中国医学科学院药物研究所 Viformyl cumarins compound, process for preparing same and pharmaceutical composition contg. same
WO2008067410A2 (en) * 2006-11-28 2008-06-05 Tahitian Noni International, Inc. Lipoxygenase and cyclooxygenase inhibition
CN101384577A (en) * 2006-02-09 2009-03-11 中外制药株式会社 Novel coumarin derivative having antitumor activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207392A (en) * 1997-07-31 1999-02-10 中国医学科学院药物研究所 Viformyl cumarins compound, process for preparing same and pharmaceutical composition contg. same
CN101384577A (en) * 2006-02-09 2009-03-11 中外制药株式会社 Novel coumarin derivative having antitumor activity
WO2008067410A2 (en) * 2006-11-28 2008-06-05 Tahitian Noni International, Inc. Lipoxygenase and cyclooxygenase inhibition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TCCM对维甲酸诱导大鼠骨质疏松的影响;王萍 等;《江苏中医药》;20040430;第25卷(第4期);全文 *
冷蒿地上部分化学成分的研究;李存芳;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20091015(第10期);第24页Fig.1，第82页第1-2段 *

Also Published As

Publication number Publication date
CN102532084A (en) 2012-07-04

Similar Documents

Publication Publication Date Title
Devi Withaferin A: a new radiosensitizer from the Indian medicinal plant Withania somnifera
Ryu et al. Astragali Radix elicits anti-inflammation via activation of MKP-1, concomitant with attenuation of p38 and Erk
Kim et al. Apoptosis of DU145 human prostate cancer cells induced by dehydrocostus lactone isolated from the root of Saussurea lappa
CN101045046B (en) Use of Brazil hemoatoxy type compound for preparing antineoplastic
Georgieva et al. Antiproliferative and antitumour activity of saponins from Astragalus glycyphyllos on myeloid Graffi tumour
Shen et al. Identification of narciclasine from Lycoris radiata (L'Her.) Herb. and its inhibitory effect on LPS-induced inflammatory responses in macrophages
Luo et al. Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo
CN106117189B (en) Acetyl group Chrysin Mannich base derivative and application thereof
KR20190003421A (en) Composition for preventing, improving or treating of fibrosis
CN108129295A (en) A kind of Diterpene derivative and its pharmaceutical composition and purposes
Joseph et al. Identification of anticancer compounds from Linum usitatissimum seed extract and their effect on HeLa cells
CN102532084B (en) One class coumarin kind compound, Preparation Method And The Use
Dai et al. Anti-tumor effects of novel alkannin derivatives with potent selectivity on comprehensive analysis
CN102038678A (en) Application of dihydroartemisinin to preparation of tumor cell autophagy induction medicament
CN104706649A (en) Application of oroxyloside to preparation of anti-tumor drugs
CN101822657B (en) Pachysandra terminalis alkaloid compound for resisting tumor metastasis
CN101565443B (en) New fir triterpene lactone compound, preparation method and application thereof
Hua et al. Hyperoside: A Review of Resources, Synthesis Pathways, Physicochemical Properties, Metabolism, Pharmacological Activities, Clinical Trials and Human Studies, Toxicology and Safety, Marketed Products, and Patents
CN101289453B (en) Preparation method of ellagic acid compound
CN102584927B (en) Class I triterpenoid, preparation method and application thereof
CN103655559A (en) Application of incarvillateine compounds in preparation of anti-breast cancer drugs
CN109771428B (en) Application of triptolide combined with erastin in the treatment of non-small cell lung cancer
Yu et al. Cantharis by photosynthetic bacteria biotransformation: Reduced toxicity and improved antitumor efficacy
Rajesh Arora et al. Himalayan mayapple: traditional uses, clinical indications and future prospects.
US20090022827A1 (en) Agent and method for eliminating malignance of cancer cells without harmful effect to normal cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant